Mazdutide common uses, half-life, side effects and more

Mazdutide is a once-weekly injection for long-term weight control and for type 2 diabetes. It acts on two gut hormone pathways at once. China approved it in June 2025 for weight management and in September 2025 for diabetes. No regulator outside China has approved it. Powder sold online under this name is not the approved pen and is not held to the same standard. Chinese approval creates no lawful supply route in the United States. The FDA has told at least one seller that offering it for human use breaks the law.

• Long-term weight control in adults with obesity in China
• Type 2 diabetes blood sugar control in adults in China
• Weight loss bought outside approved channels
• Liver fat reduction under study rather than approved
• Sleep apnea, heart failure, and alcohol use disorder in ongoing trials

Once weekly

Mazdutide starts at 2 mg once weekly under the skin for four weeks. It then moves to 4 mg weekly for four more weeks. Maintenance is 4 mg or 6 mg weekly and 6 mg is the ceiling. Someone who cannot tolerate 6 mg may drop back to 4 mg. The weight and diabetes labels share that ladder exactly. A 9 mg dose reached late-stage testing and is approved nowhere. Early studies also ran 3 mg, 4.5 mg, 10 mg, and as high as 16 mg. The diabetes label adds that the 2 mg starting dose exists to begin treatment rather than to control blood sugar. Dosing guides online circulate ladders that match no trial and no label.

• Inject under the skin of the abdomen at any time of day without regard to meals
• The label names no site other than the abdomen, rules out intravenous and intramuscular use, and keeps the needle outside a 5 cm ring around the navel
• Keep at least five days between two doses when shifting the weekly dosing day
• A dose missed by up to two days is taken at once and the next one stays on the original date
• Missing one to three weeks drops the dose one step and missing more than three weeks restarts at 2 mg
• The approved pen holds 12 mg per mL and common gray-market mixes come out several times weaker
• A 10 mg vial in 3 mL needs 180 units for a 6 mg dose and mixing it in 1.6 mL or less keeps that dose inside one syringe

About 10 days in adults with obesity or overweight and 196.3 hours in adults with type 2 diabetes. The label calls both elimination half-lives and never terminal plasma values. Levels plateau about four weeks after the dose stops changing rather than four weeks after the first injection.

Keep the pen out of light at 2 to 8 degrees Celsius and do not freeze it. If needed it may sit in its original packaging at 10 to 30 degrees for up to 30 days. A pen kept that way must not go back into the fridge and must be thrown out if it is not used within those 30 days. Do not use a pen that has been frozen even if it has since thawed.

• Nausea, vomiting, and diarrhea are the main effects and at 6 mg they reached 51, 43, and 39 percent against 6, 3, and 6 percent on placebo
• Stomach upset clusters during the dose climb and settles once the dose stops rising
• Injection-site reactions reached 7.7 percent against 1.5 percent on placebo in the weight trial
• Resting heart rate rose 2.6 beats per minute by week 48 in the weight trial while placebo showed no rise
• Gallstones appeared in 2 percent against 1 percent on placebo and one blocked gallstone caused a mild case of pancreatitis
• Low blood sugar becomes a risk when the drug is added to insulin or a sulfonylurea

Mazdutide is a synthetic analog of the gut hormone oxyntomodulin. It switches on the GLP-1 receptor and the glucagon receptor at the same time. A C20 diacid chain hangs off one lysine through a linker. That chain is the standard way to stretch a peptide to a week and is assumed to work here by binding to blood protein. The GLP-1 arm raises insulin only when blood sugar is high, calms glucagon, slows the stomach, and cuts appetite. The glucagon arm is credited with burning more energy and clearing fat from the liver. Liver fat does fall sharply on scans in people. The weight loss alone could account for that and nobody has measured energy burning in anyone taking this drug. Published reports call the two receptor effects balanced without giving a potency ratio.

The trial program is large and almost entirely Chinese. A 610-person obesity trial measured its main result at week 32. Weight fell 10.1 percent at 4 mg and 12.6 percent at 6 mg while the placebo group stayed statistically unchanged. The week 48 figures reached 11.0 and 14.0 percent. A 462-person trial of the unapproved 9 mg dose cut weight 16.7 percent over 60 weeks in a heavier group. Two diabetes trials in Nature met their blood sugar endpoints against placebo and against dulaglutide. A head-to-head against semaglutide has reported only through its sponsor and carries no peer-reviewed publication. Every late-stage trial registered so far runs only in China. No cardiovascular outcomes trial has started and nothing yet tests whether the weight loss changes heart risk.

• A boxed warning covers thyroid C-cell tumors found in mazdutide's own two-year rat study at exposures below a human dose and it is contraindicated with a personal or family history of medullary thyroid cancer or MEN type 2
• Whether those rat tumors mean anything for people is stated as unknown and a shorter mouse study found none
• Pregnancy and breastfeeding both rule out use and the label says to stop at least three months before trying to conceive
• Vomiting and diarrhea can dehydrate a person enough to injure the kidneys and both labels ask for kidney checks at the start and at every dose rise
• The weight label calls for periodic heart rate checks and says to stop if resting heart rate stays raised
• Delayed stomach emptying has left food in the stomach before anesthesia and both labels say to account for that before a procedure